中國生物製藥(01177.HK)收購禮新醫藥餘下95.09% 代價最高9.5億美元
中國生物製藥(01177.HK)公布,收購禮新醫藥餘下95.09%股權至全資擁有,代價不超過9.5億美元。剔除禮新醫藥估計現金及銀行存款約4.5億美元,公司付款淨額約5億美元,將以內部資源及銀行借款撥付。
禮新醫藥擁有全球領先的抗體發現和ADC技術平台,包括腫瘤微環境特異性抗體開發平台,新一代抗體偶聯藥物平台以及免疫細胞銜接器平台,收購事項將進一步強化集團在前沿分子類型和腫瘤免疫領域的研發技術能力,加速全面創新發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.